Jul 14, 2026 4:30 pm EDT Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
Jul 9, 2026 7:00 am EDT Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
Jun 25, 2026 4:30 pm EDT DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
Jun 23, 2026 7:00 am EDT Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
Jun 19, 2026 7:00 am EDT Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 16, 2026 7:00 am EDT Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
May 13, 2026 7:00 am EDT Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
May 12, 2026 7:00 am EDT Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
May 5, 2026 7:00 am EDT Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month
